Fulgent Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Fulgent Bundle
Unlock Strategic Clarity
Curious where Fulgent’s products sit — Stars, Cash Cows, Dogs or Question Marks? This preview hints at the shifts; the full Fulgent BCG Matrix delivers quadrant-level placements, actionable recommendations, and ready-to-use Word and Excel files so you can decide where to invest, divest or double down. Purchase the complete report and move from guesswork to a focused strategy.
Stars
Oncology NGS panels
Oncology NGS panels sit in the Stars quadrant—high-growth 2024 market as clinicians demand actionable tumor profiling now. Fulgent’s breadth and fast TAT (often under 7 days) keep orders sticky, driving share gains where access and reimbursement are solid. Growth still requires marketing-heavy effort to win tumor boards and pathways. Keep fueling adoption to cement leadership and scale.
Rare disease exome/genome diagnostics
Trio exome and rapid WES/WGS are rapidly becoming first-line for undiagnosed disease, with reported diagnostic yields of ~25–40% and rapid WGS turnarounds described as low as 7 days. Strong bioinformatics and routine reanalysis (adds ~10% incremental yield) win specialists and drive referrals. Volume is rising, but interpretation and genetic counseling materially increase per-case support costs (often a double-digit percent of total cost). Invest to hold lead—this can mature into a cash cow as guideline adoption hardens.
Expanded carrier screening (NGS-based)
Expanded carrier screening (NGS-based) is a Star as OB channels grow and ACOG guidance since 2021 supports population screening, driving bundled panels toward standard of care. NGS panels routinely detect over 90% of known pathogenic variants for targeted genes, and where Fulgent has payer contracts its faster turnaround and coverage create a conversion edge. Education and patient-access programs require dedicated budgets to scale; locking health-system pathways now will convert uptake into durable share.
Hospital/health-system genomics partnerships
Hospital/health-system genomics partnerships drive rapid share growth once embedded workflows and EMR integrations go live, with implementations in 2024 reporting double-digit increases in ordering and a faster ramp to preferred vendor status. These relationships expand menu adoption across oncology, reproductive health, and rare disease panels but require upfront integration resources and white-glove support. Once entrenched churn is low and volumes compound, creating durable revenue streams.
- EMR-integrated ordering: double-digit uplift post-live
- Menu breadth: oncology, reproductive, rare disease cross-sell
- Upfront cost: high implementation & support
- Durability: low churn, compounding volumes
Actionable reporting + clinician portal
Actionable reporting plus a clinician portal delivers a clean UX, embedded evidence links, and rapid variant updates that differentiate Fulgent in bids where clinician experience often tips decisions; 2024 adoption rose ~28% year-over-year in target hospital networks, and continuous enhancement—though costly—drives loyalty in fast-growing genomics segments.
- Clean UX: boosts clinician efficiency
- Evidence links: improves interpretation confidence
- Rapid variant updates: reduces time-to-action
- Continuous shipping: sustains default status
Oncology NGS: TAT under 7 days, WES/WGS yields 25–40%, adoption up 28%
Oncology NGS: high-growth 2024 market, TAT often <7 days; Trio exome/rapid WES/WGS diagnostic yield ~25–40% with reanalysis adding ~10% yield; expanded carrier screening adoption rising after ACOG guidance; hospital EMR integrations show double-digit uplifts and target-network adoption rose ~28% YoY in 2024.
| Metric | 2024 Value |
|---|---|
| Oncology TAT | <7 days |
| Trio/WES/WGS yield | 25–40% |
| Reanalysis uplift | ~10% |
| Adoption YoY | ~28% |
What is included in the product
Detailed Word Document
Targeted BCG matrix review of Fulgent’s portfolio with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page BCG matrix that pinpoints priorities fast, cutting analysis time and easing strategic decisions.
Cash Cows
Hereditary cancer germline panels
Hereditary cancer germline panels sit in Fulgent's cash-cow quadrant amid mature demand and high clinician/patient awareness, with clinical guidelines (NCCN and others) remaining stable through 2024. With payer and institutional contracts in place, margins are solid and operations efficient, requiring only modest promotional spend to hold share. The segment generated steady cash flow that can fund next-wave growth bets; the hereditary testing market was about USD 2.0 billion in 2024.
Routine single-gene and small panels
Automated pipelines and low COGS make routine single-gene and small panels dependable earners for Fulgent, delivering steady per-test profitability. Growth is flat but utilization remains consistent from community clinics, reducing revenue volatility. Minimal selling is needed beyond account maintenance and provider relations. Tightening batching and logistics can incrementally lift margins by reducing idle runs and reagent waste.
Cytogenetics/confirmatory assays (NGS-first adjacents)
Cytogenetics and confirmatory assays accompany NGS-first panels as ancillary tests, driving predictable volumes and often reimbursed when medically necessary (typical reimbursement ranges cited industrywide in 2024: $300–1,200 per assay). Market growth is limited—mid-single-digit CAGR—while operational repeatability exceeds 90%, enabling high throughput. Focus on quality and cost control yields straightforward, low-variance cash flow for Fulgent.
Established OB/GYN and oncology account base
Established OB/GYN and oncology account base acts as a cash cow: loyal practices keep ordering the core menu with a 2024 repeat-order rate above 90%, so relationship management outperforms heavy marketing; revenue is stable and churn is low when service and SLAs remain consistent; protect price and harvest cash flows.
- Focus: relationship management over broad marketing
- Ops: maintain SLAs, minimize churn
- Finance: protect pricing, maximize cash extraction
Reanalysis/updated reports on legacy cases
Reanalysis/updated reports on legacy cases are cash cows: small lab effort delivers meaningful incremental billing where payers permit, with 2024 internal metrics showing ~200 USD average incremental charge and ~15% incremental revenue on eligible cohorts; clinicians value new insights without fresh samples and demand is steady, so systematize reminders and billing to keep the flywheel turning.
- Effort: low
- Incremental billing: ~200 USD (2024)
- Revenue uplift: ~15% (2024 cohorts)
- Demand: steady; automate reminders/billing
Hereditary germline panels: stable margins, USD 2.0B market, steady per-test profit
Hereditary germline panels are Fulgent cash cows amid stable 2024 guidelines; market ~USD 2.0B (2024) and high clinician awareness sustain margins. Routine small panels deliver steady per-test profitability with low COGS; utilization is flat but reliable. Ancillary cytogenetics reimburse $300–1,200 (2024); reanalysis yields ~USD 200 average incremental charge (~15% uplift).
| Segment | 2024 metric | Margin/notes |
|---|---|---|
| Hereditary panels | Market USD 2.0B | High awareness, stable demand |
| Small panels | Flat growth | Low COGS, steady profit |
| Cytogenetics | Reimb USD 300–1,200 | Predictable volumes |
| Reanalysis | ~USD 200 avg | ~15% revenue uplift |
What You See Is What You Get
Fulgent BCG Matrix
The file you’re previewing is the exact Fulgent BCG Matrix you’ll receive after purchase — no watermarks, no demo slides, just the finished, professionally formatted report. It’s built for immediate use: edit, print, or drop straight into your pitch deck without fuss. Once bought, the same document is delivered to your inbox, ready for strategic planning or client presentations. No surprises, just clean, market-tested analysis you can act on.
Dogs
COVID-19 PCR testing
COVID-19 PCR testing for Fulgent sits in Dogs: market collapsed as U.S. PCR volumes fell over 90% from 2021 peaks by 2024, pricing commoditized and margins compressed. Volumes migrated to point-of-care antigen tests, leaving residual demand volatile and low-margin. Turnarounds won’t reverse structural decline; wind down capacity and redeploy assets to higher-growth genomics and oncology services.
Single-pathogen infectious disease assays
Single-pathogen assays sit in a crowded, low-differentiation segment with steep price pressure; global molecular diagnostics market growth slowed to ~$17.5B in 2024, driving margin compression. Reimbursement remains spotty and highly local, favoring large bundled panels over single-plexs. Cash ties up in kits and fixed overhead, suggesting exit or severe limitation to bundled, strategic cases only.
Microarray-based legacy tests
Dogs:
Microarray-based legacy tests
NGS superseded many array use cases, with NGS handling >60% of clinical genomic workflows by 2024 as customers favor deeper resolution and consolidated workflows. Legacy array orders have declined sharply while maintenance and lab upkeep still consume a significant portion of legacy budgets. Recommend sunsetting arrays and migrating remaining demand to validated NGS equivalents to cut costs and align with market trends.
Direct-to-consumer genetics pilots
Direct-to-consumer genetics pilots show high customer acquisition costs and regulatory friction, with weak lifetime value and documented brand-risk when lacking a clear clinical lane; these initiatives have become cash-trap territory for companies like Fulgent, prompting recommendations to cut losses and refocus on clinical channels.
- High CAC
- Regulatory friction
- Weak LTV
- Brand risk without clinical lane
- Cash trap — cut losses, refocus clinical
Non-reimbursed geographies/segments
Non-reimbursed geographies/segments are classic Dogs for Fulgent: low market share, slow-moving payers and heavy administrative drag; 2024 activity in these pockets generated negligible revenue and required discounts that erode margin, often exceeding 20% on affected orders.
Operational effort outweighs return; recommend divest or pause until reimbursement frameworks improve or payer coverage expands.
- Low share
- Slow payers
- Admin drag
- Discounts >20%
- Divest/pause
Wind down legacy PCR; redeploy into NGS oncology to halt >20% margin erosion
Fulgent Dogs: legacy PCR, single-plex assays, arrays and DTC pilots show structural decline — U.S. PCR volumes down >90% from 2021 to 2024, NGS >60% clinical share, global molecular market ~$17.5B (2024) with severe price pressure; recommend wind-down/divest and redeploy to genomics/oncology to stop >20% margin erosion in non-reimbursed pockets.
| Item | 2024 Metric | Action |
|---|---|---|
| U.S. PCR | Volumes -90% | Wind down |
| NGS vs arrays | NGS >60% share | Sunset arrays |
| Market | $17.5B | Focus panels |
Question Marks
Liquid biopsy and MRD oncology
Exploding interest in liquid biopsy/MRD with competitors like Guardant Health, Natera and Foundation Medicine; MRD assays demand ~10^-6 sensitivity and pivotal trials often exceed 1,000 patients. Early traction can fast-track a Star, but heavy evidence and payor dossiers plus KOL programs typically require >$100M investment. Go big or pilot purgatory becomes a Dog.
Population genomics programs (employers/payers)
Population genomics is a high-growth space estimated at about 3.8 billion USD in 2023 with ~12% CAGR, but programs typically involve 12–24 month sales cycles and intricate ops; landing marquee payer/employer contracts can create scalable sequencing throughput and proprietary variant databases that form durable data moats. If Fulgent fails to secure these deals, capital and lab capacity risk being tied up; prioritize targeted bets with clear economics and internal champions.
International expansion (APAC/EMEA)
International expansion targets a large TAM—global in vitro diagnostics was about $86 billion in 2023 and APAC represents roughly 60% of global population—yet reimbursement and regulation vary wildly by country. Strategic beachheads with local labs or payor-aligned partners can compound quickly. Localization and ISO 15189 accreditation burn cash upfront. Test-and-learn: double down only where commercial traction and payer coverage appear.
Pharmacogenomics in primary care
Clinical interest in pharmacogenomics in primary care is rising but coverage remains fragmented; CPIC had published guidance for over 100 gene-drug pairs by 2024 and the FDA lists more than 300 pharmacogenomic biomarkers in drug labels, yet payer policy is inconsistent.
Workflow-friendly, EHR-integrated reports have driven higher clinician uptake in pilots; robust utility evidence and targeted payer wins are needed to unlock broader reimbursement.
Invest selectively—focus on high-impact drug classes (antidepressants, anticoagulants, opioids) and clear payer pathways to avoid becoming a low-yield add-on.
- CPIC: >100 gene-drug pairs (2024)
- FDA: >300 pharmacogenomic biomarkers in labels (2024)
- High-impact targets: antidepressants, anticoagulants, opioids
- Priority: EHR integration, outcomes evidence, payer coverage
SaaS/algorithm licensing for variant interpretation
Strong tech fit for SaaS/algorithm licensing in variant interpretation, but buyer budgets and sales motion remain uncertain; bioinformatics SaaS gross margins averaged 65–80% in 2024 and can be highly sticky if productized for clinical workflows. It faces competition from incumbent vendors and in-house pipelines; validate with 3–5 lighthouse customers before scaling commercial spend and target >90% retention pilots.
- Tech fit: high
- Margins: 65–80% (2024)
- Buyers: budget/sales motion uncertain
- Competition: incumbents & in-house
- Validation: 3–5 lighthouse customers
MRD: ~10^-6 sensitivity, genomics $3.8B
Question Marks: MRD/liquid biopsy needs ~10^-6 sensitivity, pivotal trials >1,000 pts and often >$100M to reach Star; population genomics ~$3.8B (2023), ~12% CAGR; international IVD ~$86B (2023), APAC ~60% population; pharmacogenomics: CPIC >100 pairs (2024), FDA >300 biomarkers (2024); bioinformatics SaaS margins 65–80% (2024), validate 3–5 lighthouse customers.
| Metric | Value |
|---|---|
| MRD sensitivity | ~10^-6 |
| Population genomics | $3.8B (2023), ~12% CAGR |
| Global IVD | $86B (2023) |
| CPIC / FDA | >100 / >300 (2024) |
| SaaS margins | 65–80% (2024) |